Business Description
Avacta Group Plc is a UK-based biopharmaceutical company focused on developing targeted cancer treatments that deliver powerful drugs directly to tumors while reducing harm to healthy tissue. Its pipeline includes AVA6000, a modified form of an established chemotherapy drug, alongside AVA6103 and AVA7100, which use the company's proprietary technology to concentrate treatment at the tumor site. Founded in 2003 and headquartered in London, Avacta operates across the UK, South Korea, and other international markets.
